The study was published in Gastroenterology, the journal of the American Gastroenterological Association.
This study, the largest double-blind study of an anti-TNF agent in children with Crohn’s disease, found that more than 80 percent of children with moderate to severe Crohn’s disease responded to the therapy within a month. By six months, about 34 percent of patients were in clinical remission, and after a year, more than 28 percent were in remission.
Related Articles on the American Gastroenterological Association:
Study: Aspirin Reduces Risk of Barrett’s Esophagus
Gastroenterologist Dr. Mark Donowitz Pens Op-Ed on Challenges to Medical Research
AGA Urges Obama to Sign PDUFA Into Law
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
